VivoSim Labs

VIVS

Current ValuationThe current P/E ratio is -0.21, above the reasonable range, cheaper than 11.11% of the time in the past 1 years, and the industry ranks 114/605, the industry Median -1.91.

-0.214xP/E
Stock price$0.16Earnings per share$-0.74

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
021426384

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GILDUSGilead Sciences
-60.16x150.60%$194.91B
MRNAUSModerna
-25.67x17.00%$80.90B
CSLLYUSCSL Limited
-25.55x--$65.90B
NTRAUSNatera
-300.79x5.57%$57.86B
RVMDUSRevolution Medicines
-22.75x61.94%$40.23B
ROIVUSRoivant Sciences
-101.60x146.69%$27.05B
BNTXUSBioNTech SE
-11.52x19.30%$22.53B
INSMUSInsmed
-23.72x75.01%$20.76B
BBIOUSBridgebio Pharma
-19.25x28.60%$13.32B
SMMTUSSummit Therapeutics
-14.49x19.79%$12.41B
MDGLUSMadrigal Pharma
-32.22x51.30%$10.47B
PCVXUSVaxcyte
-9.29x47.91%$9.89B
KYMRUSKymera Therapeutics
-30.77x5.24%$9.22B
TWSTUSTwist Bioscience
-65.23x28.71%$8.92B
IBRXUSImmunityBio
-8.88x151.32%$8.81B
CYTKUSCytokinetics
-9.69x6.85%$8.67B
ARWRUSArrowHead Pharma
-25.76x35,923.70%$8.24B
SYREUSSpyre Therapeutics
-54.20x45.60%$8.14B
ABVXUSAbivax SA
-16.91x22.99%$7.87B
IONSUSIonis Pharma
-12.91x49.51%$7.30B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.